Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex’ Yaz Receives Another “Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite the setback, the firm continues to expect FDA approval for the low-dose oral contraceptive in the first quarter of 2006.

You may also be interested in...



Berlex’ YAZ Clears FDA For Contraception; April Launch Planned

A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.

Berlex’ YAZ Clears FDA For Contraception; April Launch Planned

A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.

Loestrin 24 Approved As First 24-Day Oral Contraceptive

Warner Chilcott beats out Berlex' Yaz as the first oral contraceptive approved in the U.S. with 24 active hormone days.

Topics

UsernamePublicRestriction

Register

PS063088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel